Nanobiotix S.A.

Healthcare · Biotechnology · France

Last price 33.8 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.71B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Th...